Scarica l'app Stockscreener
224.03
1.43%
-3.25
Precedente Chiudi:
$227.28
Aprire:
$227.28
Volume 24 ore:
1.06M
Relative Volume:
0.81
Capitalizzazione di mercato:
$29.98B
Reddito:
$4.29B
Utile/perdita netta:
$577.22M
Rapporto P/E:
53.23
EPS:
4.2086
Flusso di cassa netto:
$641.34M
1 W Prestazione:
-3.97%
1M Prestazione:
-12.47%
6M Prestazione:
-26.68%
1 anno Prestazione:
-51.66%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$222.00
$238.96
Portata 52W:
$197.81
$485.36
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
224.03 | 29.98B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-15 | Ripresa | UBS | Buy |
| 2026-08-19 | Iniziato | BMO Capital Markets | Outperform |
| 2026-08-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2026-05-19 | Iniziato | Citigroup | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research
Alnylam Pharmaceuticals (ALNY) Cuts 2026 Guidance After AMVUTTRA Sales Beat, Is It Fully Valued - Simply Wall Street
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - Yahoo Finance
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - The Motley Fool
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index? - Yahoo Finance
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered - The National Law Review
ALNYLAM PHARMACEUTICALS INC (ALNY.MX) Q4 FY2025 earnings call transcript - Yahoo Finance
What Has Changed For Alnylam Pharmaceuticals Since Its 52% Fall - Simply Wall Street
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Forecasts - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum - ChartMill
Alnylam Pharmaceuticals, Inc. (ALNY) options chain - Yahoo Finance Australia
UBS Adjusts Alnylam Pharmaceuticals Price Target to $354 From $550, Maintains Buy Rating - Yahoo Finance
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results - Alnylam
Alnylam Pharmaceuticals (NASDAQ:ALNY) Share Price, Forecast & Analysis - Stocks Down Under
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut? - Yahoo Finance
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
BofA Securities Adjusts Alnylam Pharmaceuticals Price Target to $336 From $346 - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Stock Looks Pricey Despite A 51% Slide - Yahoo Finance
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - GlobeNewswire Inc.
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% - Trefis
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Peri - Alnylam
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - wboc.com
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire Inc.
An Alnylam (ALNY) officer proposes a $399K share sale that includes shares to cover an equity-award tax bill. - Stock Titan
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% - Simply Wall Street
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% - simplywall.st
Alnylam Shares Fall as Investors Weigh Earlier 2026 Outlook Reset Against a Near-Term Data Wait - Quiver Quantitative
Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - benzinga.com
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN) - The Globe and Mail
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Stock Forecast & Analyst Predictions - simplywall.st
Alnylam Pharmaceuticals (ALNY) Stock Forecast and Price Target 2026 $ALNY - MarketBeat
A former football player’s symptoms were attributed to football or aging. His heart diagnosis came late. - Stock Titan
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM - Times Argus
Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside - NAI500
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) - Seeking Alpha
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Yahoo Finance
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - TradingView
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - Yahoo Finance
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SUPRAN BRYAN | Officer |
Oct 02 '26 |
Proposed Sale |
226.88 |
1,758 |
398,862 |
0 |
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Option Exercise |
0.00 |
3,830 |
0 |
5,412 |
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Proposed Sale |
299.51 |
3,830 |
1,147,123 |
0 |
| SCHULMAN AMY W | Director |
May 13 '26 |
Option Exercise |
70.20 |
11,250 |
789,750 |
23,211 |
| McLaughlin Melissa | Officer |
Apr 06 '26 |
Proposed Sale |
320.10 |
2,286 |
731,749 |
0 |
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 06 '26 |
Sale |
330.42 |
2,286 |
755,329 |
9,443 |
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 02 '26 |
Sale |
319.59 |
1,624 |
519,014 |
11,729 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 05 '26 |
Sale |
323.98 |
658 |
213,177 |
20,569 |
| Fitzgerald Kevin Joseph | Officer |
Mar 05 '26 |
Proposed Sale |
323.69 |
658 |
212,988 |
0 |
0.17%
2.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):